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Delivery of lmmunocontraceptive Vaccines
for Wildlife Management
Lowell A. Miller

Abstract: lmmunocontraceptive technology appears to be

a v ao e approacn for pop~lat~on
contro oin- sance spec es
01 wllo le Tne aom n strat on of mm,noconrracept~ve
vaccines is presently performed by syringe injection or by
remote delivery via darts or biobullets. In order for
immunocontraception to be successful in wide application to
free-roaming animals, the vaccine must be delivered in an
ora form Recent aovances .n mo ec.. ar o o ogy.
mmJno ogy ana patnodogy of rn-cosa nfect~onsg ve LS
tools to develop effective oral vaccines. Oral vaccies

A growing need for nonlethal methodology for population control of nuisance or damaging species of
wildlife has fostered research in immunocontraceptive
vaccine technology. Kirkpatrick et al. (1990) demonstrated that reproductive rates of feral horses can be
reduced by vaccinating these animals with native
porcine zona pellucida (PZP). Turner et al. (1992)
demonstrated that PZP was effective as an
immunocontraceptive in the white-tailed deer
(Odocoileus virginianus). Recent advancements in
immunology and molecular biology have made it
possible to produce and administer genetically engineered contraceptive vaccines, thus making reproductive control a very promising alternative in wildlife
management.
In a previous study by Turner and Kirkpatrick
(1991), the vaccine was delivered by darting or
biobullet. This remote delivery is valuable for special
applications. However, in order for this technology to
have wide application, one must have a mode of
application that can disseminate the vaccine to a large
segment of a wildlife population at a reasonable cost
(Garrott et al. 1992).
The most logical means of vaccine application to
free-roaming animals is by oral delivery. Oral vaccination, however, is not without its problems (Bloom
1989). Because vaccines are proteins, they need a
protective mechanism to prevent digestion in the
gastrointestinal tract. Baiting with vaccines should be
as species specific as possible and yet be designed to
reach a large proportion of the selected wildlife
population. Oral delivery of immunocontraceptive
vaccines is an untested area of technology that will

encapsulated in either biodearadable micros~heres
syntnet c aones ve ~posomei,or non, r~ ent' ve vectors
nolo prom se as a ~ractlcala ~ ~ r o a cforn rnm~nocontrace~r
on
of free-roaming wildlife. lsGes of safety, species sPeciicity,
and field application of the vaccine will need to be
addressed.
Keywords: W lo fe vacc nes, mmt,noconrracept on.

tacc ne vectors, ora vacc ne oe .very

need several years of developmental research before
the first vaccines are available for entry into the
registration process.
The purpose of this paper is to review the
immunological concepts of vaccination and how they
may apply to immunocontraception, review the current
technology of oral immunization, and propose some
applications for oral immunocontraception in freeroaming pest vertebrates.

Reproduction and Immunology
Mammalian and avian reproduction involves interaction of spermatozoa and oocytes contributed by the
male and female, respectively. Both these gametes
have unique surface glycoprotein receptors against
which an immune response can be elicited. The
development of these gametes and corresponding
hormones is under the control of follicle-stimulating
hormone (FSH) and luteinizing hormone (LH), gonadotropins secreted from the pituitary and flowing
through the bloodstream to the gonads. Secretion of
the gonadotropins is in turn regulated by gonadotropin-releasing hormone (GnRH), which also has a role
in sexual receptivity that is in addition to its regulation
of FSH and LH release and the stimulation of ovulation. lmmunocontraception involves producing antibodies against these reproductive hormones and
gamete proteins that will interfere with their biological
activity.
The power and efficiency of vaccines in combating
infectious diseases is well recognized and accepted.
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Figure 1. Reproductive ' s e l f antigens are made "foreign" by
coupling them (conjugation) to a protein foreign to the animal.

Injecting the conjugate into the animai produces antibodies to the
self antgen as well as the forelgn protein.

The vast majority of vaccine research is concerned
with the development of new and improved vaccines
against viral and bacterial diseases. Antidisease
vaccines are based on using immunologically foreign
antigens, such as surface glycoproteins of viruses and
bacteria, to stimulate the immune system to form
antibodies that attack live viruses and bacteria just as
they would the glycoproteins.

normal flora and self-proteins from pathogens through
a process called immune tolerance.

In order to understand the concepts of
immunocontraception, one must understand how the
immune system defends itself against outside organisms (Silverstein 1989). Development of infections
and resulting immune responses are constantly in
process because people live in a world filled with
micro-organisms. Every facet of our existence brings
us into contact with bacteria, fungi, viruses and a
diversity of parasitic or potentially parasitic life forms.
Yet we possess a rich, harmless, natural microflora on
all body surfaces, within all body orifices, and throughout most of the gastrointestinal tract. Even vital
digestive functions are mediated partly by the gastrointestinal flora. The body is able to differentiate

Antifertility vaccines are directed against selfreproductive antigens, either hormones or proteins, to
which the recipient is normally immunologically
tolerant (Jones 1983). These antigens are made
"foreign" by coupling them to a protein foreign to the
animal. The resultant vaccine induces immunity which
interferes with the biological activity of that particular
antigen. The result can be infertility (fig. 1).
An immunological approach to contraception is
attractive because it requires only periodic vaccination. The approach is physiologically sound in the
sense that antibodies induced in the target animal
interfere with reproduction without the constant
medication.
lmmunocontraception occurs when fertility is
reduced by means of antibodies attaching to and
interfering with the biological activity of hormones or
reproductive tract proteins. lmmunization against
most reproductive antigens generally gives rise to a
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reversible response. Antibodies decline in the course
of time, and animals regain fertility (Dunbar and
Schwoebel 1988).

Systemic Vaccination
Dose amount, frequency and timing, immunogenicity
of the antigen vaccine preparation, and mode of
immunization all influence the immune response. The
nature of the immune response required for an antifertility vaccine is equivalent to the response obtained
by immunization. Rendering reproductive self-antigens
immunogenic involves conjugating these self-molecules
with foreign substances in order to break the state of
tolerance associated with these molecules. These
vaccines must be designed to react with macrophages
(the antigen presenting cells) as well as with the two
immune-processing cells (T and 6).For example, the
T cells receive the antigen from the macrophage and
present the foreign material to the B cells. Enhancement of B-cell activity is essential to the production of
high levels of antibodies as well as creation of B
memory cells to that specific antigen.
Traditional immunization has always been
associated with adjuvants (nonspecific immune
stimulants). The most common adjuvant is Freund's
complete adjuvant (FCA). This substance is a mixture
of mineral oil and killed bacteria cells. Booster injection is performed with Freund's incomplete adjuvant
(FIA) (minus the killed bacteria) to prevent abscesses
at the injection site. The protein to be injected is
dissolved in water and mixed with the oily adjuvant to
form a water-in-oil emulsion. This emulsion provides a
depot at the injection site allowing a slow release of
the immunogen to the immune system. The optimal
length of antigen presence for maximum antibody
production is unknown; however, if antigen presence
is too short, the antibody quantity is suboptimal.
Chronic presence of antigen leads to antigen tolerance and a lack of antibody production response.
The immune system, both systemic and mucosal,
seems to respond best by giving a priming dose
followed in several weeks by a booster dose. A single
dose produces a short-lived antibody response and

does not result in a long-lasting memory response.
Many times, the best response is observed when the
animal is boosted several months after the original
antigen exposure. Continued presence of the antigen
for several weeks is important for a long-lasting
immune response. Slow-release vehicles such as
microspheres or liposomes can provide this effect.
The standard form of vaccination involves
50-100 pg of antigen for small animals (mice to
rabbits) and 200-400 pg for larger animals. The
antigen is mixed with FCA to produce a thick water-inoil emulsion. This emulsion is injected into the animal
using multiple subcutaneous, intradermal, or intramuscular sites. Booster doses use the same or slightly
less antigen in FIA. When incomplete Freund's is
used for boosters, abscesses at the site of injection
generally do not form. Highly immunogenic antigens
can produce sufficient antibody with doses of 5 to 10 pg.
Scientists at the Denver Wildlife Research
Center (DWRC) have demonstrated that the hypothalamic hormone GnRH, made foreign by coupling to
keyhole limpet hemocyanin (KLH), can sterilize both
sexes of wild Norway rats (Rattus norvegicus) for up
to a year. White-tailed deer immunized with a porcine
glycoprotein (PZP), the zona pellucida that surrounds
all mammalian oocytes, remained sterile for at least
two breeding seasons.

Oral Vaccination
Mucosal Immune System
The pharyngeal and intestinal mucosae represent a
major interface with the external environment and
come in contact with food and products of food
digestion, ingested micro-organisms, drugs, and the
vast quantity of resident flora that populate the distal
small intestine and colon (Mestecky 1987).
The intestine is the body's largest immunologic
organ. It comprises 70-80 percent of all of the body's
immunoglobulin (lg) (antibody)-producing cells and
produces more secretory lg (SIgA) than the total
production of serum lg in the body. The primacy of the
intestine in making lg is not surprising because the

Contraception in Wildlife Management

majority of infectious disease organisms are first
encountered through the intestinal mucosal membranes. The main antibody produced by the mucosal
immune system is SIgA. Intestinal SlgA response is of
relatively short duration, lasting from 2 to 4 weeks.
The SlgA system exhibits potent immunologic memory
and can be repeatedly stimulated by renewed contact
with antigen. Systemic IgG production may also be
stimulated by oral vaccination, and the presence of
IgG as a result of vaccination may be detected in
serum years later. It is the serum IgG that provides
the long-term interference with the biological activity of
reproductive hormones and proteins.
Immune follicles, including tonsils, are located in
the pharyngeal area at the entrance to both the
respiratory and digestive tracts. The pharyngeal area
of the throat may be considered the first line of mucosal
defense and immune response. As a second line of
defense, thousands of lymphoid follicles are located in
the distal portion of the small intestine. Aggregates of
these follicles called Peyer's patches (PP) are also
found throughout the small intestine. The lumenal
surface of PP are covered by an epithelium which
contains a unique cell type termed the M cell (Childers
et al. 1990). Intact viruses and micro-organisms and
particulate antigens up to 10 bm in size are taken up
by M cells for antigen delivery to the underlying
lymphoid cells. This uptake of micro-organisms
enhances the ability of the host to respond immunologically to a microbial challenge and fight off an
infection. These antigens activate T and B cells and,
along with macrophages, soon migrate out of the PP
to the mesenteric lymph nodes and into the bloodstream via the thoracic duct, thereby presenting the
antigen to the systemic immune system (fig. 2).

Oral Delivery of Antigen to the Intestine
Many factors can influence the expression of mucosal
immunity to a specific antigen. Most proteins are
rather poor immunogens when given orally. This is
the reason so few vaccines are currently administered
by this route.
Effective mucosal immunogens appear to have
certain characteristics: (1) They are not degraded in
the mucosal environment (e.g., the intestine); (2) they
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Figure 2. The small intestine contains thousands of immune
follicles. Aggregates of these follicles are called Peyer's patches
(PP). Their surface contains a unique cell type. the M cell, which
takes up intact viruses, bacteria, and particulate antigens up to
10 pm in size. Once inside the PP the antigens are processed by
the macrophage and presented to the immune system.

can bind to and penetrate into the mucosal epithelium
(thus allowing efficient uptake in the PP, as typified by
cholera toxin (CT), one of the most effective mucosal
immunogens known; and (3) they may also have
adjuvant immunostimulating activity (Holmgren et al.
1992, McGhee and Kiyono 1994).
Live micro-organisms with mucosal adhesive
properties are highly effective mucosal immunogens;
killed and inert antigens without mucosal binding
properties are poor mucosal immunogens. Most food
antigens are poor mucosal immunogens because they
are rapidly degraded into nonimmunogenic fragments
in the mucosal environment. Food antigens generally
do not bind to epithelial receptors.
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As pointed out previously, immune lymphoid
follicles are located in the pharyngeal area as well as
distal portion of the small intestine. Most oral immunization studies use the gavage technique, which
means the antigen was delivered into the stomach
through a blunted needle. Lavage delivery, in which
the antigen is delivered in the pharyngeal area, can
stimulate the immune follicles in this area as well as in
the small intestine. Delivery of unencapsulated protein
antigens to the pharyngeal area may be an effective
means of oral immunization since it precedes the
stomach's digestive enzymes.
Enteric-coated capsules are commonly used for
delivery of drugs to the small intestine. Enteric
capsules are resistant to acid but are soluble in the
alkaline solution of the small intestine. They provide
only one-half of the formula of effective antigen
delivery (i.e., protection from the stomach) because
they generally cannot be made small enough to be
taken up by the PP. Also, enteric-coated vaccines can
get the protein past the stomach, dissolve, and
release the antigen in the small intestine, but proteolytic enzymes in the small intestine may digest
these proteins into nonimmunogenic peptides before
they are absorbed by the immune cells. The safest
way to deliver the antigen orally is to protect it until it is
taken up by the PP and delivered to macrophages.
Combining two approaches-(I) enteric coating
or using delivery vehicles that slow the intestinal
degradation of the antigen and (2) targeting the
vaccine design to attach to the immune follicles with M
cell binding-could lead to an effective antigen uptake
and potentiation of mucosal immune response.
The quantity of antigen used in oral immunization
depends on how well the antigen is protected from
degradation and how immunogenic it is. The antigen
dose may vary from 12.5 pg to 1 g per dose, with
larger animals receiving the larger quantities of
antigen. Most studies indicate that two doses given
3-4 weeks apart are needed to produce a long-lasting
immune response. Ahren et al. (1993) found that a
third dose given within 3 weeks was counterproductive, probably because SlgA stimulated from the
second dose interfered with the uptake of the antigen.

Two oral doses of a live salmonella vector
produced IgG responses similar to the response of a
systemic vaccination of the killed form of the same
vaccine (Morona et al. 1994). Oral boosting after
42 days was needed for this response. A single dose
or boosting after 14 days gave a much lower antibody
titer.
Scientists at DWRC have demonstrated that
white-tailed deer can be successfully vaccinated using
a genetically engineered Bacillus Calmette Guerin
(BCG). These bacteria were designed to deliver an
outer surface protein A (Osp A) antigen onto the
surface of the bacteria. A good IgG response to the
Osp A antigen was demonstrated after two oral doses
of bacteria. DWRC is also testing different oral
immunocontraceptive vaccines in wild Norway rats.

Immune Tolerance
The constant systemic presence of antigen can induce
a state of immune tolerance in which antibody production is reduced (Ernst et al: 1988). This process is
probably a protective mechanism to prevent the
animal from an excessive immune response. What is
excessive depends on the antigen. However, gram
quantities of antigen are generally considered excessive. The mucosal immune system seems to have a
built-in limitation in terms of the magnitude of response
to any single immunogen (oral immune tolerance).
This limitation is in contrast to the systemic immune
system, which responds vigorously to nonself-antigens. It would be impossible and perhaps even
harmful for the intestine to mount a vigorous immune
response to each of the thousand foreign antigens it
encounters each day. The term "oral tolerance" is
used when the animal's immune system ceases to
respond to a given antigen. Oral tolerance is commonly found when a large dose of an antigen is given
or when the antigen is highly immunogenic and
therefore likely to cause the animal harm due to a
severe immunologic reaction. An example of this
second type of antigen is a bacterial surface lipoprotein, lipopolysaccharide (LPS).
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Stok et al. (1994) discovered that conjugating
cholera toxin (CT) to ovalbumin and revaccinating with
the conjugate orally could reverse an earlier ovalbumin-induced oral immune tolerance.

Receptor Binding o n
Intestinal Mucosal Surface

Oral Vaccine Delivery Vehicles
Synthesized Vectors
Microspheres-Biodegradable microspheres have
been used as a slow-release antigen-delivery system.
These spheres are copolymers of DL-lactide and
glycolide that are synthesized to contain trapped
antigen. When these spheres are injected into the
host animal, they dissolve, slowly releasing the
antigen. The microsphere can be designed to deliver
the antigen for from 1 week to several months, depending on the size and the polymer ratio of lactide to
glycolide. In most applications, microspheres have
been given systemically; however, they can be given
orally (Eldridge et al. 1989 and 1990). Microspheres
of 1-10 pm are taken up by the PP; however, the
efficiency of the uptake is only 1-2 percent. The
remaining microspheres pass out of the intestine. The
microspheres taken up by the PP dissolve, releasing
the antigen directly to the immune system.
Liposomes-Liposomes are spherical, artificial
biological membranes made up of phospholipids and
cholesterol (Alving et al. 1991). Liposomes contain
lipids, chosen for their stability in the gastrointestinal
tract. These lipids can protect the antigen from
gastrointestinal degradation. Cholesterol in the
liposome stabilizes the membrane and makes it
attractive to the macrophage because of its lipophilic
nature. The phospholipids in liposomes are
amphipathic, i.e., they possess a hydrophilic (polar)
head and hydrophobic (hydrocarbon) tail. In an
aqueous medium, phospholipids exist as micelles or
bilayers; the polar heads are at the outer layer due to
their affinity to water (fig. 3).
Because of the nature of the membrane, the
liposome mimics the microbial cell when the liposome
is presented to the immune system. During the
synthesis of the liposome, antigen is trapped inside,
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Figure 3. Liposomes are spherical artificial biological membranes.
During the synthesis of the liposome. antigen is trapped inside the
sphere. The resuit is a protective vehicle for oral delivery of the
antigen. Cholera toxin B 1s attached to the outer surface of the
liposome to provide intestinal adhesive propertes Ths adhesion
to the intestine enhances immune response to the liposome and t s
antigen contents.

providing a protective vehicle for delivery of the
protein antigen. The liposome acts as an antigen
microcarrier and an adjuvant, capable of targeting the
antigen directly to the PP. Liposomes have been used
to deliver the antigen systemically or orally. When
given orally, liposomes with a diameter less than 10 pm
are preferentially taken up by the PP and may persist
there for up to several weeks (Alving et al. 1991).
Liposomes, especially small ones (1-2 pm), can be
expected to reach the blood circulation rapidly through
the intestinal lymphatics.
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Liposomes Enhanced With Cholera Toxin B-Until
recently, based on the relatively poor mucosal immunogenicity of soluble antigens, it was widely assumed
that only live vaccines would effectively stimulate a
mucosal immune response (Nedrud and Lamm 1991).
Recent understanding of the mechanisms by which
pathogenic viruses and bacteria colonize and infect
the intestinal tract gives researchers new tools to
develop successful oral vaccines. For example, a
bacterium must survive the presence of the stomach's
acid and proteolytic enzymes in order to infect the
small intestine successfully. After surviving the
stomach, the bacterium must have surface adhesive
properties allowing it to adhere to and colonize the
intestinal wall, resulting in an infection. Bacteria
without these adhesive properties will be carried out of
the gut with undigested food material.
Because of their lipophilic nature, liposomes are
avidly taken up by the macrophages (Rooijen 1990).
However, the liposome must bind to the mucosal
surface of the intestine before it can be taken up. This
rnucosal adhesive property increases the mucosal
uptake resulting in greater efficiency and allowing one
to use a smaller oral vaccine dose. The most common liposome adhesive is the bacterial lectin CT, a
member of a family of enterotoxins produced by
several strains of enteropathogenic bacteria (Ahren et
al. 1993, McGhee 1992, Mestecky and McGhee
1989). Lectins have multiple binding sites and can
bind to receptors on the liposome as well as to intestinal receptors.
CT consists of two subunits-alpha (CTA), which
has the toxic properties, and beta (CTB), which has
the adhesive or mucosal binding properties. CTB
bound to the liposome provides the adhesive properties without the toxicity associated with CT. The CTB
bound to the ganglioside GM, receptor inserted in the
liposome also binds to the ganglioside GM, receptors
present on the surface of intestinal epithelial cells,
thus providing the binding activity needed for mucosal
antigens (fig. 3).
Heat-labile toxin (LTB) from pathogenic Escherichia
coli bacteria represents another adhesive lectin that
can be attached to liposomes to provide an intestinal
mucosal binding.

Live Vectors
The common forms of existing vaccines are killed
bacteria or modified live viruses that, when injected
into the host animal, produce immunity by producing
antibodies against surface proteins of these organisms. New techniques in molecular biology have
introduced the concept of delivering the vaccine
surface proteins in harmless live bacteria or viruses
that act as a delivery system and therefore are called
vectors. Vectors can be used to deliver the vaccine
proteins systemically or orally. Vectors that are
effective orally must have the ability to attach or
adhere to mucosal surfaces. After attachment, these
vectors are taken in by the mucosal immune system
and thereby deliver the vaccine proteins directly to the
immune system. Nonattaching vectors would be
carried out of the intestine with the food bulk.
The ideal immunocontraceptive vaccine should
be species specific; however, at the present time,
species specificity is difficult to achieve. Live vectors
can help provide species specificity by employing
species-specific viruses or bacteria, such as
swinepox, which was used to develop a vaccine
carrier for the control of the feral hog.
Viral Vectors-The DNA representing several vaccines has been inserted into harmless viruses. The
inserted DNA synthesizes the vaccine protein as the
virus multiplies in the host animal, thereby vaccinating
the animal. The most noted viral vector has been the
vaccinia virus a member of the poxvirus family (Moss
1991). This virus has been genetically engineered to
deliver a rabies vaccine. Given orally, the harmless
vaccinia virus multiplies in the body and synthesizes a
surface rabies protein. Antibodies produced against
this protein protect the animal against a future rabies
virus infection. This viral construct has been used
successfully in eliminating most of the rabies in foxes
and raccoons in Europe (US. Department of Agriculture, Animal and Plant Health Inspection Service
1991). The viral vectors can also be designed to
contain immunocontraceptive proteins (Morell 1993).
Bacterial Vectors-As in viral vectors, bacteria can
be genetically rendered harmless (nonpathogenic) and
have immunocontraceptive vaccine DNA inserted into
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them. This recombinant bacteria can deliver a
irnmunocontraceptive protein, coded by the inserted
DNA, to an animal host. The two bacterial vectors in
use today are an attenuated BCG and a double genedeleted Salmonella typhi bacillus. Both bacteria
vectors are considered safe and have been used in
many vaccine delivery applications. S. typhistrains,
with deletion of two genes, are avirulent in animals,
birds, and humans. These strains retain the intestinal
adherence property found in unmodified Salmonella
spp, and are absorbed by the intestinal immune cells.
It appears to be safe and effective as a live vector for
oral delivery of immunocontraceptive vaccines.
Morona et al. (1994) found that two oral doses of
a live Salmonella construct elicited serum IgG responses
that were comparable to intramuscular vaccination
with formalin-killed Salmonella. Therefore, it appears
that-even with live vectors-one needs at least two
presentations of the antigen.
Live bacterial and viral vectors would be more
economical to produce than the synthetic vectors;
however, the public acceptance and safety issues
have to be addressed.

Field Applications of Oral
lmmunocontraceptive Vaccines
Oral immunocontraceptive protein vaccines are
untested. The protein vaccine must be mixed into
liquid or solid baits that require some protection from
the environment for at least several weeks. The bait
must be attractive to a large segment of the target
animal population. Present vaccine designs would
require baiting an animal population twice about one
month apart. Vaccine application should start about
2 months before the start of the breeding season. If
the vaccine itself is not species specific, the delivery
system should be. Problems d multiple visits to the
bait and repeat baiting of dominant animals need to be
understood in the practical application of population
control. With the exception of the vaccinia virus rabies
vaccine, safe use of recombinant bacterial and viral
vectors has yet to be proven in a field application.

Summary
lmmunocontraceptive vaccines delivered by injection
or by darting have been shown to be a viable technique in preventing conception when used in confined
or limited field applications. However, in order for
immunocontraception to have widespread success
against free-roaming animal populations, the vaccine
must be delivered in an oral form in a designed bait.
Because oral vaccines are proteins, they are subject
to digestion by stomach gastric contents; therefore,
the oral vaccine must be protected by some form of
encapsulation. Inconsistent antibody responses to
multiple oral doses may be due to the presence of
intestinal IgA antibodies, which may prevent uptake of
the antigen by the intestinal immune system.
Recent understanding of the mechanisms by
which pathogenic viruses and bacteria colonize and
infect the intestinal tract give us new tools to develop
successful oral vaccines. Synthesized vectors, such
as biodegradable microspheres and liposomes, can
protect the protein vaccines and deliver them to the
mucosal immune cells. Liposomes can be designed
to contain lectin receptors that mimic the adhesive
properties of intestinal pathogens, thereby enhancing
their mucosal uptake and immunogenic properties.
Understanding the molecular genetics of oral
pathogenic bacteria and viruses allows one to attenuate these virulent strains and insert the DNA of the
vaccine to be expressed. Because these vaccine
proteins are "self," they need to be linked to the DNA
of a more immunogenic protein and be expressed
together by the live vector. The use of these attenuated live vectors to deliver immunocontraceptive
vaccines can provide economical vaccines of a
consistent nature. These new tools should provide the
basis for successful oral immunocontraceptive vaccines of the future. Successful field application of
these vaccines needs careful study and is yet to be
attempted.
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